Literature DB >> 7974391

Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans.

S Valentin1, A Larnkjer, P Ostergaard, J I Nielsen, O Nordfang.   

Abstract

Tissue Factor Pathway Inhibitor (TFPI) is a heparin binding protein and injection of heparin causes a release of TFPI to plasma. In order to understand the binding between TFPI and heparin in more detail we have in this study looked into some of the heparin characteristics and their importance for the TFPI-heparin interaction. We have developed an assay based on the use of heparin-Sepharose micro columns in order to compare small quantities of heparin fractions as well as different glycosaminoglycans on a weight basis for their TFPI binding. In this assay a glycosaminoglycan in solution compete with heparin-Sepharose for TFPI binding. Size fractionated heparin was analyzed for binding to TFPI, and a clear dependency on the molecular weight was observed. The highest TFPI binding capacity was found for fractions with a molecular weight above 10,000 Da, while no binding was measured below 2,000 Da. No difference in TFPI binding appeared after fractionation of heparin according to its affinity towards antithrombin, thus indicating that TFPI binding does not require the specific antithrombin binding site. A heparin fraction of 10,000 Da was fractionated on a mono Q column, resulting in four fractions with different charge densities. The charge density turned out to be a very important parameter for the binding of TFPI. A number of different glycosaminoglycans were tested and the following order of TFPI affinity was found: heparin >> dermatan sulphate > heparan sulphate > chondroitin sulphate C. No binding was observed for chondroitin sulphate A or hyaluronic acid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974391     DOI: 10.1016/0049-3848(94)90066-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

Authors:  Qing Ma; Mahmut Tobu; Christopher Schultz; Walter Jeske; Debra Hoppensteadt; Jeanine Walenga; Umberto Cornelli; John Lee; Robert Linhardt; Israel Hanin; Jawed Fareed
Journal:  Thromb Res       Date:  2006-07-07       Impact factor: 3.944

2.  Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

Authors:  Shuchong Pan; Thomas A White; Tyra A Witt; Anca Chiriac; Cheri S Mueske; Robert D Simari
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

Review 3.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

4.  Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix.

Authors:  Julie A Peterson; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-08       Impact factor: 10.514

5.  Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.

Authors:  Mari Tinholt; Benedicte Stavik; William Louch; Cathrine Rein Carlson; Marit Sletten; Wolfram Ruf; Grethe Skretting; Per Morten Sandset; Nina Iversen
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

6.  Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin.

Authors:  Walter Jeske; Ahmed Kouta; Rick Duff; Varun Rangnekar; Manoj Niverthi; Debra Hoppensteadt; Jawed Fareed; Yiming Yao
Journal:  Clin Appl Thromb Hemost       Date:  2018-09-09       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.